Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Healthcare Biotechnology
Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the... see more

Recent & Breaking News (TSX:RVX)

Resverlogix (T.RVX) jumps 45% on positive RVX-208 trial findings

Gaalen Engen January 15, 2014

Resverlogix Announces Combined RVX-208 findings from SUSTAIN & ASSURE Phase 2b Trials

Canada NewsWire January 15, 2014

Resverlogix (T.RVX) up 15% on industry publication recognition

Gaalen Engen January 3, 2014

Publications Confirm RVX-208 is a Unique Selective BET Bromodomain Antagonist

Canada NewsWire January 2, 2014

Resverlogix Completes Enrollment of Phase 2 Clinical Trial of RVX-208 in Patients with Pre-Diabetes Mellitus

Canada NewsWire December 23, 2013

Resverlogix digs deeper in to trial data, finds reason for poor July results

Chris Parry November 4, 2013

Resverlogix Announces Two New Findings from the ASSURE Trial Relating to Inflammation and Plaque Vulnerability

Canada NewsWire November 4, 2013

InvestorsGuru.com 32 Filtered Mid-Day Market Movers Recap

Investors Guru September 7, 2013

Further Analysis of the ASSURE Data Finds a Responder Group for RVX-208 with Statistically Significant Regression of Coronary Atherosclerosis

PR Newswire September 3, 2013

Further Analysis of the ASSURE Data Finds a Responder Group for RVX-208 with Statistically Significant Regression of Coronary Atherosclerosis

Canada NewsWire September 3, 2013

Resverlogix Announces a Corporate Update Conference Call & Webcast

Canada NewsWire August 29, 2013

Resverlogix Announces a Corporate Update Conference Call & Webcast

PR Newswire August 29, 2013

Resverlogix Closes $1.6 million Private Placement

Canada NewsWire August 14, 2013

Resverlogix Announces $1.6 million Private Placement

Canada NewsWire August 12, 2013

InvestorsGuru.com 19 Filtered Mid-Day Market Movers Recap

Investors Guru July 6, 2013

Resverlogix Corporation is Featured as the Daily Momentum Gainer to Watch on Smallcappower.com

Newsfile July 5, 2013

AQM Copper soars 129% on investment news: Canadian market movers

Elizabeth Walters July 2, 2013

Resverlogix to host Conference Call & Webcast with Q&A

Canada NewsWire June 28, 2013

Resverlogix to host Conference Call & Webcast with Q&A

PR Newswire June 28, 2013

IIROC Trade Resumption - RVX

Canada NewsWire June 27, 2013